The aging population, the increasing number of lifestyle diseases and the increasing proportion of difficult-to-cure illnesses in the EU demands the use of modern medicine and modern medical technology. Such a situation leads to an increase of funds spent on the health sector. Therefore the...

In this paper we analyse public sector efficiency in the new member states of the European Union compared to that in emerging markets. After a conceptual discussion of expenditure efficiency measurement issues, we compute efficiency scores and rankings by applying a range of measurement...

In this paper we analyse public sector efficiency in the new member states of the EU compared to that in emerging markets. After a conceptual discussion of expenditure efficiency measurement, we compute efficiency scores and rankings by applying a range of measurement techniques. The study finds...

Access to healthcare is formed according to the characteristics of the supply and demand. While siting hospitals, ?equity' in access to healthcare should be taken as a basis for all segments of society, and necessary measures should be taken to ensure that vulnerable groups benefit from health...

The report is a result of the Ageing, Health Status and Determinants of Health Expenditure (AHEAD) project within the EC 6th Framework programme. The objective ofthe research was to present the model of future health care system revenues and expenditures in selected Central and Eastern European...

The speed and scope of COVID-19 took the United States by surprise. No state was adequately prepared to handle the pandemic, and no federal agencies had enough knowledge to offer sufficient guidance. As the country continues to cope with the crisis, the extent to which regulatory restrictions on...

In this paper we document a process of price convergence in the European market for pharmaceutical products and relate it to access to innovative medicines in individual countries. The EU is a peculiar case study, where free circulation of goods coexists with pricing policies designed and...

Ensuring affordable access to novel medicines has been identified as a policy priority among OECD and EU countries, yet systematic monitoring of the various dimensions of access is lacking. Previous efforts to measure access have focused primarily on one or at most two of these dimensions, such...